Satellos Bioscience Inc MSLE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $6.35
- Day Range
- $6.53–6.82
- 52-Week Range
- $5.45–13.18
- Bid/Ask
- $6.45 / $6.86
- Shares Outstanding
- 21.22M
- Market Cap
- $138.97M
- Volume/Avg
- 12,973 / 41,875
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 21
- Website
- https://www.satellos.com
Valuation
Metric | MSLE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.26 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MSLE |
|---|---|
Quick Ratio | 10.68 |
Current Ratio | 11.22 |
Interest Coverage | — |
Quick Ratio
MSLE
Profitability
Metric | MSLE |
|---|---|
Return on Assets (Normalized) | −62.88% |
Return on Equity (Normalized) | −110.19% |
Return on Invested Capital (Normalized) | −71.49% |
Return on Assets
MSLE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|x@YwBJx | LOCK|V@b!$ | $138B | |||
| Moderna Inc MRNA | LOCK|Pr??P@ | LOCK|J&b | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|$Zn$Ny | LOCK|bgKK> | $93B | |||
| argenx SE ADR ARGX | LOCK|D<lbJ< | LOCK|y^ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!RcS<K | LOCK|ySN | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|@L^w<FMy | LOCK|mpzx | $30B | |||
| Incyte Corp INCY | LOCK|R<$t<zM | LOCK|#w@ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|B^Fb#pZ | LOCK|&y | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#Ns$ZJ | LOCK|$W>G | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|^TtH$<F | LOCK|w!h | $15B |
United States